L'Oréal S.A. (LRLCY) Stock Price & How to Invest

L'Oréal S.A. is a Paris-based beauty group with more than 35 international brands sold in about 150 countries. It makes money by selling skincare, makeup, hair care and fragrance through four divisions: Consumer Products (L'Oréal Paris, Maybelline, Garnier), the largest by sales; L'Oréal Luxe (Lancôme, Yves Saint Laurent Beauté, Armani, Prada, Valentino, Aesop and, since April 2026, Creed); Dermatological Beauty (La Roche-Posay, CeraVe, Vichy, SkinCeuticals); and Professional Products (Kérastase, Redken), sold through salons. The Bettencourt Meyers family owns roughly a third of the company and Nestlé about a fifth. LRLCY is an unsponsored ADR that trades in dollars and tracks the Euronext Paris share (ticker OR) adjusted for the euro-dollar rate.

Growth reaccelerated in 2026. Sales for 2025 were ~€44.05 billion, up 4.0% like-for-like, with an operating margin of 20.2% and earnings per share of €12.71. In the first half of 2026, sales reached ~€23.78 billion, up 6.8% like-for-like (5.8% reported, held back by a stronger euro), and the operating margin rose to a record 21.3%, even as brand investment went up. Every division grew: Professional Products by 12.6% and Dermatological Beauty by 11.3% like-for-like, with Luxe at 5.4% and Consumer Products at 4.1%. Every region grew too, led by SAPMENA-SSA (South Asia, the Middle East and Africa) at 13.9%, North America at 8.6% and North Asia at 4.6%. Diluted EPS excluding one-off items was €7.40, up 4.8%.

The debate is about price rather than quality. Few large consumer companies have grown sales and margins as reliably, which is why the shares trade around 33 times trailing earnings, far above most consumer-staples peers. Supporters point to the ~€4 billion Kering Beauté deal, a healthier China trend and fast-growing dermatology brands as reasons the faster pace can last. Skeptics note that a 2025 slowdown hit the shares hard, that consensus already expects about 6.8% revenue growth for 2026, and that a premium multiple leaves little cushion if growth cools.

Valuation is the main risk. At roughly 33 times trailing earnings, a modest growth miss can move the shares sharply, as happened in October 2025 when third-quarter like-for-like growth of 4.2% came in below expectations. Consensus now looks for third-quarter 2026 revenue of about €11.2 billion, up roughly 8.6% on a reported basis, so the bar for the October 22 release is high. Consumer Products, the largest division, grew only 4.1% in the first half, and mass beauty in the US and Europe faces competition from cheaper indie and private-label brands. China's recovery has been uneven, and travel retail remains volatile. Kering Beauté adds integration risk and ties part of Luxe to the health of fashion houses whose brands L'Oréal licenses rather than owns. Professional Products' double-digit growth partly reflects pricing, which may not repeat. For US holders, a stronger dollar reduces returns, the OTC ADR can trade thinly with wider spreads, and French withholding tax applies to dividends.

3 analysts publish price targets on LRLCY, averaging $103.17 against a $90.90 price as of October 2026, or +13.5%. The published targets run from $100.00 to $107.00, a narrow spread, and the ratings split 4 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LRLCY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on L'Oréal S.A.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Dermatological Beauty. Dermatological Beauty is the group's most profitable division and one of its fastest growing. The most optimistic published target, $107.00, assumes this works close to its best case.

The case against. Valuation is the main risk. The most pessimistic target, $100.00, is roughly what LRLCY is worth if this bites instead.

Read the full bull and bear case on LRLCY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see L'Oréal S.A.'s investor relations page or your broker.

• Revenue (TTM): ~€45.4 billion (~$53 billion)
• H1 2026 sales growth (like-for-like): ~6.8% (Q2 alone ~6.0%)
• Operating margin (H1 2026): ~21.3%, a first-half record
• Market cap: ~$242 billion
• P/E: ~33x trailing, ~26x forward
• Dividend (2025, per ordinary share): €7.20, ~1.9% yield on the ADR

L'Oréal has long traded at a premium to consumer-staples peers because of its steady growth and expanding margins. First-half 2026 net profit excluding one-off items was ~€3.96 billion, up 4.7%, and reported attributable net profit was ~€3.55 billion. LRLCY traded between about $78.82 and $95.48 over the past year. Analysts expect 2026 revenue of roughly €47.0 billion, up about 6.8%, and around €50.0 billion in 2027. The third-quarter sales release on October 22, 2026 (after the Paris close) is the next test of whether the faster first-half pace carried into the second half.

Other names that sit close to LRLCY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LRLCY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LRLCY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LRLCY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

L'Oréal is a high-quality, high-multiple beauty leader growing mid-to-high single digits with record margins, so the shares hinge on whether that pace holds, starting with third-quarter sales on October 22.

Whether LRLCY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LRLCY a buy or a sell?, and where the stock could go from here in the LRLCY stock forecast.

For income investors, whether LRLCY pays a dividend and how the payout looks is covered in does LRLCY pay a dividend? And to weigh LRLCY against a peer, read the full side-by-side comparisons: LRLCY vs EL and LRLCY vs COTY.